We were delighted to catch up with Dr Susan Samson (Mayo Clinic, Jacksonville, FL, US) to discuss the one-year outcomes of oral octreotide capsule use in patients with acromegaly.
‘One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly.‘ (PRESENTATION NUMBER: OR14-3) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
- What have been the major challenges of injectable therapies for people living with acromegaly? (0:18)
- What are the challenges of producing a somatostatin based oral therapy? (1:41)
- What did the CHIASMA OPTIMAL study show us about the efficacy and safety of oral octreotide capsules compared with injectable somatostatin analogs in acromegaly? (2:46)
- What were the findings of the recent open label extension study of CHIASMA OPTIMAL? (4:24)
- Which patients are most likely to respond to oral octreotide capsules and in whom are they contraindicated? (6:13)
Disclosures: Dr Susan Samson was a site PI and steering chair for the Chiasma OPTIMAL trial.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ENDO 2021 (Virtual).
Share this Video
Related Videos In Pituitary Disorders
Diego Ferone, ENDO23: Efficacy and safety of octreotide subcutaneous depot in patients with acromegaly
Extended-release formulations of the somatostatin analogues, octreotide and lanreotide, are first-line medical therapies for patients with acromegaly who have contraindications for, or are not cured by, surgical intervention and/or radiotherapy. touchENDOCRINOLOGY are joined by Dr Diego Ferone (University of Genova, Italy) to discuss the efficacy and safety of CAM2029 in acromegaly evaluated in a 6-month, […]
Thierry Brue, ECE 2023: Novel and emerging therapies for acromegaly
Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. It occurs when the pituitary gland produces too much growth hormone (GH). touchENDOCRINOLOGY were delighted to speak with Prof. Thierry Brue (Aix-Marseille University, Marseille, France) about the current treatment paradigm for acromegaly and the latest therapies that are currently being developed. The abstract ‘Management […]
Susan Samson, ENDO 2021: Outcomes from the CHIASMA OPTIMAL Open-Label Extension Study
We were delighted to catch up with Dr Susan Samson (Mayo Clinic, Jacksonville, FL, US) to discuss the one-year outcomes of oral octreotide capsule use in patients with acromegaly. ‘One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly.‘ (PRESENTATION NUMBER: OR14-3) was presented at the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!